Real World Study on Erlotinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer
Condition: Efficacy and Safety of Erlotinib Combined With Bevacizumab in EGFR Mutation Positive Advanced Non-squamous Non-small Cell Lung Cancer Intervention: Drug: erlotinib combined with Bevacizumab Sponsor: Hunan Province Tumor Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study | Tarceva